Clinical Trial Update: A Study to Evaluate the Safety and Efficacy of a Modigraf® Based Immunosuppression Regimen in De Novo Pediatric Allograft Liver and Kidney Transplantation Recipients [Phase 4]

View source ↗

Summary

Phase 4 study assessing a Modigraf-based immunosuppression regimen in de novo pediatric liver and kidney transplant recipients has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Kidney Transplantation
• Liver Transplantation

Drugs mentioned

• Modigraf (Tacrolimus)

Snippet

Sponsor: Astellas Pharma China, Inc. | Conditions: Liver Transplantation, Kidney Transplantation | Phase 4 | Status: COMPLETED